Recent human studies have reported that SGLT2 inhibitors effectively control blood glucose levels and reduce insulin requirements without serious adverse effects in T1DM when administered in combination with insulin (Yang et al., 2017). The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.